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 Traditional prognostic tools tended to overestimate the risk of cancer recurrence 
and recommend adjuvant chemotherapy plus tamoxifen for most of early stage breast 
cancer (ESBC) patients. 21-gene assay is validated as a better predictor that may 
support this decision-making process. Although the cost-effectiveness of 21-gene assay 
in developed countries is well researched, because of with huge differences in 
epidemiology, treatment, and healthcare system, these results cannot be generalized to 
China easily. This study aimed to evaluate the potential economic impact of 
incorporating 21-gene assay on Chinese ESBC patients.  
A cost-effectiveness analysis with a decision tree and Markov model was 
performed based on the validation studies of 21-gene assay and published literature. A 
hypothetical cohort of 10,000 Chinese female patients with LN-, ER+, HER2- ESBC at 
the age of 45 were chosen to undergo treatment guided by either 21-gene assay or 
NCCN guideline Chinese version. Costs were estimated under the Chinese health care 
system, from the health care provider’s perspective, reported in 2008 Chinese Yuan (¥). 
Total costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratio (ICER) were estimated as outcome measures.  
Under base case analysis with the AC regimen as adjuvant chemotherapy, 21-gene 
assay saves ¥11 125 (US$1 628) with a higher QALY of 0.30 year per patient over 10
  
iv 
years. Replacing the chemotherapy with TC regimen results in an even larger cost 
saving of ¥13 285 (US$ 1 934) but less effective gain of 0.24 year. Although overall 
results were sensitive to the cost of 21-gene assay and NCCN guideline risk 
classification accuracy, they were still considered as highly cost-effective, in terms of 
the threshold defined by the World Health Organization (WHO).  
In conclusion, 21-gene assay-guided treatment is considered to have cost saving 
and quality of life gain compared with NCCN guideline-guided treatment from a 
Chinese health care system perspective. The results of this study should inform better 
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1.1  Breast Cancer 
Breast cancer refers to a malignant tumor that starts in the cells of the breast, most 
commonly from either lobules or ducts.1 The majority of breast cancer cases occur in 
women.2 With more than 1.2 million new cases diagnosed every year worldwide, this is 
by far the most prevalent cancer among women.3 In 2009, the estimated global costs of 
treating new cases of breast cancer reached US$ 24 billion, ranking third among all 
cancers.4  At least 3.8 million years of life were lost (YLL) to breast cancer for women 
between the ages of 25 and 64 worldwide in 2000.5 Thus, the burden of illness from 
breast cancer has become a global concern. 
According to the WHO Cancer Fact Sheet 2008,3 breast cancer incidence rates are 
high (greater than 80 per 100,000 women) in developed regions (except Japan) and low 
(less than 40 per 100,000 women) in most of the developing regions. For example, the 
incidence rate in China, within the Eastern Asia region, is around 25 per 100,000 
women; while the U.S., within the Northern American region, has an incidence rate 
around 80 per 100,000 women, almost 3 times higher than the rate in eastern Asia.  
Several possible explanations are available for this huge incidence difference 
across regions. First is race. Studies have shown that incidence differs between different 
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racial groups.6,7 Even within the same region, for example, in the U.S., Whites have a 
much higher incidence rate, compared to Blacks, Asians and Hispanics.2 Another issue 
is life style. Diet habits,8-10 alcohol consumption,11 age when first giving birth12 and 
other life style factors are well-known risk factors for breast cancer. People share little 
in common on these factors among different regions.  
However, other than the explanation from an epidemiology point of view, the 
incidence differences might also be due to the differences in life expectancy. In Africa, 
the female life expectancy is around 40-50 years13; many women may be dying before 
they get the chance to develop a breast cancer. In addition, in Western countries, many 
women have regular screening, either mammogram, clinical breast exam or breast self-
exam. Yet, in developing countries, especially in rural areas, screening rates are 
incredibly low.14,15 Since most breast cancer studies are done in Western countries with 
higher income and longer life expectancy, evaluation of interventions for detection and 
treatment in developing countries are lacking.  
As to mortality rates, in both developing and developed countries, mortality rates 
are much lower than incidence rates, less than 20 per 100, 000 women.3 This is due to 
early detection among Western countries and the high survival rate in early stage breast 
cancer (ESBC) patients. In the U.S., ESBC has a 5-year survival rate higher than 95%.2 
That is why early detection through screening is so important and why optimizing care 





1.2  Early Stage Breast Cancer 
1.2.1 Breast Cancer Stage 
The TNM staging system is the most often used system to describe the growth of 
breast cancer. In this system, T describes the size of tumor and growth into nearby 
tissues, N tells if the cancer has spread to lymph nodes, and M indicates the extent of 
cancer in distant organs. Based on TNM categories, breast cancer is identified as stage I, 
stage II (IIA or IIB), stage III (IIIA, IIIB or IIIC), or stage IV. ESBC includes cancers in 
stages I, IIA, IIB, and IIIA; cancers that may have spread to nearby lymph nodes but not 
to distant parts of the body.16 
There are four tumor features that are important to stage the cancer and decide the 
treatment16,17:  (1) Tumor size – in early stage breast cancer patients, the tumor is 
usually smaller than 5 cm16; (2) Lymph node status – lymph node status, often 
abbreviated as LN+ or LN-, indicates whether the cancer has spread to nearby lymph 
nodes16; (3) Hormone receptor status – estrogen and progesterone are hormones in the 
body that start the growth of breast tissue. In some types of breast cancer, these 
hormones also help tumors to grow. These types of tumors are called estrogen receptor–
positive (ER+), progesterone receptor–positive (PR+), or both. They tend to grow more 
slowly and are less likely to spread to the lymph nodes16,18,19; (4) HER2 (human 
epidermal growth factor receptor 2) status – if the cells are HER2 positive (HER2+), the 
growth of cancer cells is more likely to be rapid because there are more messages for 




1.2.2 Treatment for ESBC Patients 
Different strategies are involved in ESBC treatment. For most women, surgery, 
either breast-conserving surgery or mastectomy, is the first step.16,17 Breast-conserving 
surgery, which is less radical, consists of lumpectomy, which only removes the tumor 
and some surrounding tissue, while mastectomy removes the whole breast and possibly 
some of the lymph nodes. Both surgeries aim to remove the tumor. Both surgeries have 
similar survival and recurrence-free benefit for patient.20   
After the surgery, patients usually receive further treatment to kill any cancer cells 
that might remain in the body and prevent the recurrence. Tamoxifen is the standard 
hormone therapy usually given to hormone receptor positive patients. However, a 
difficult and important decision for these patients is whether to undergo additional 
adjuvant chemotherapy. Studies have shown the likelihood of distant recurrence in 
patients treated with tamoxifen alone is about 15% at 10 years.21 That is to say, at least 
85 percent of patients would be over-treated with chemotherapy if it were offered to 
everyone.  Although chemotherapy might add 4% absolute recurrence-free benefit for 
patients,22 it is expensive and brings adverse events, such as infections, neutropenia, 
anemia, and nausea. Almost all chemotherapy patients undergo chemotherapy-related 
adverse events and more than 10% of them get a serious or life-threatening adverse 
event.23,24 These adverse events will lead to more cost and poorer quality of life.  
 
1.3  Risk Classification 
To avoid unnecessary chemotherapy and adverse events, physicians need to 
classify the risk of recurrence for each patient. If the patient has high risk of recurrence, 
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they will provide the adjuvant chemotherapy, and if the patient is less likely to get 
recurrence, they will only give them the hormone therapy. Traditionally, risk 
classification relies on traditional guidelines based on clinical and pathologic tumor 
features as well as patient characteristics, including tumor size, hormone receptor status, 
HER2 status, and age of the patient. Free online software called Adjuvant!Online(AOL) 
is also available to assist the decision-making process. However, numerous studies have 
shown that physicians tend to overestimate the risk of cancer recurrence with these 
traditional tools and recommend adjuvant chemotherapy plus tamoxifen for most of the 
patients.25 
Advances in genomics have led us to multiple molecular tools performed on an 
individual patient’s tumor and tissue to achieve more accurate risk classification.26 
Among these tools, 21-gene assay is the only tool that has been studied in phase III 
trials and incorporated into major clinical guidelines. 16,27-29 Figure 1.1 shows the 
timeline for ESBC patients after incorporating 21-gene assay. 
 
 
Figure 1.1 Timeline for early stage breast cancer patients 
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1.4  Twenty-one Gene Assay 
The 21-gene assay (Oncotype DX® Breast Cancer Assay) is a reverse 
transcriptase-polymerase chain reaction (RT-PCR) assay, developed by Genomic Health 
Inc., Redwood City, CA. Performed on breast cancer tumor samples that were obtained 
from surgery, 21-gene assay analyzes the presence of specific mRNA for 16 cancer-
related genes and 5 reference genes. After the assay, Recurrence Score (RS) predicting 
chemotherapy benefit, and the 10-year risk of distant recurrence is provided for the 
individual patient, ranging from 0 to 100.  Then, patients can be classified into 3 
recurrence risk categories: low risk (RS<18), intermediate (18<=RS<=30), and high 
(RS >30).21 
A prospective study of archived tissue from 668 LN-, ER+ patients, the National 
Surgical Adjuvant Breast Cancer Project (NSABP) B-14 trial, has demonstrated the risk 
of distant recurrence at 6.8%, 14.3%, and 30.5%, for RS low, intermediate, and high 
group, respectively.21 Another study of archived tissue from 651 LN-, ER+ patients, 
NSABP B-20 trial, compared chemotherapy plus tamoxifen with tamoxifen alone and 
demonstrated that the RS high group has the maximum benefit of 28% reduction in 10-
year distant recurrence risk from adjuvant chemotherapy.22  
More recently, TransATAC study proved the predictive value of 21-gene assay for 
LN+ patients30 and SWOG-8814 study found the chemotherapy benefit for this subset 
of patients.31 Japan had its own validation study among 200 LN- patients and 280 LN -
/+ patients and found similar results.32 Opened in January 2011, the RxPONDER Trial 
(Rx for Positive Node, Endocrine Responsive Breast Cancer) will evaluate 
chemotherapy benefits for 4,000 patients with LN+ breast cancer who have low to 
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intermediate RS results.33 In addition, an international trial called TAILORx (Trial 
Assigning Individualized Options for Treatment (Rx)) is also ongoing to assess the 
chemotherapy benefit for RS intermediate patients.34   
Based on the results of these clinical trials, 21-gene assay, as the only clinically 
validated multigene assay for breast cancer patients, is incorporated into 3 major clinical 
practice guidelines to provide prognosis information. Table 1.1 lists the 
recommendations regarding 21-gene assay in these three guidelines: NCCN (National 
Comprehensive Cancer Network),16 ASCO (American Society of Clinical Oncology),28 
and St Gallen guidelines generated from the St Gallen International Breast Cancer 
Conference (2009).27 They all support 21-gene assay as an option for LN-, ER+, HER2- 
ESBC patients to predict the benefit of chemotherapy. 
 
Table 1.1 Recommendations regarding 21-gene assay in guidelines 
NCCN Guidelines Consider use in >0.5 cm, HR+, HER2- negative disease pT1, 
pT2, or pT3; and pN0 or pN1mi (<=2 mm axillary node 
metastasis) 
ASCO Guidelines Newly diagnosed patients with node-, ER+ breast cancer 
who will receive tamoxifen 
St Gallen Consensus 
Guidelines 
Predict chemotherapy benefit among patients with HR+, 





1.5  Cost-effectiveness problem 
Studies have validated the effectiveness of 21-gene assay. Two published 
prospective studies indicated that 21-gene assay would improve the decision-making 
and change treatment recommendation in 31.5% and 32% of breast cancer cases, and 
most of the changes were from chemotherapy in addition to tamoxifen to tamoxifen 
alone (22.5% and 21%).35,36 In addition, NSABP B-20 showed that the 21-gene assay 
will predict the magnitude of chemotherapy benefit.22 However, compared with the free 
traditional prognostic tools, the cost of the test itself is expensive. In the U.S., the 
manufacturer suggested retail price is around $4,000.37 In the cost-effectiveness plane 
shown in Figure 1.2, the situation falls into the I Quadrant, which indicates higher cost, 
better outcome, and a positive ICER. Thus, with the huge cost saving from avoiding 
unnecessary chemotherapy and the expensive price of 21-gene assay itself, a cost-
effectiveness question arises.  
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1.6  CEA Studies Conducted So Far 
To solve this cost-effectiveness problem, economic evaluations of 21-gene assay 
have been reported from North American,37-42 South American,43 European,44 and Asian 
countries.32,45,46  
 
1.6.1 Example Model 
Figure 1.3 is a CEA example model, done by Hornberger in 2005, and several later 
studies developed their models based on this study.32,37,46 In this model, patients were 
assigned to the 21-gene assay testing group and no 21-gene assay group. Both groups 
received NCCN guideline risk classification first. The 21-gene assay group underwent a 
reclassification into either RS intermediate/high group or RS low group. Patients 
received different chemotherapy based on their HER2 receptor status. All patients who 
received chemo went into a toxicity subtree and then go to the outcome subtree. All 
patients that did not receive the chemo directly go to the outcome subtree. 
 
1.6.2 Comparison of Studies 
By 2011, 11 CEA studies had been conducted to evaluate the economic impact of 
21-gene assay; all were modeling studies performing decision trees or Markov models. 
Table 1.2 lists these 11 studies. Five of them were studies in the U.S., while UK, 
Canada, Brazil, and Israel each had one. Two studies were done in Japan, one based on 
the U.S. validation study46 and one based on the Japanese validation study.32 Brazil is 
the only developing country conducting a CEA study on this topic.  
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Figure 1.3 Example model of CEA study for 21-gene assay39 
 
Hypothetical cohorts are analyzed as the base case in studies, expect for 
Hornberger et al. (2011).37 Different age and clinical characteristics were chosen as the 
base case. According to the validation trial, the study was based on mean age at 
diagnosis of breast cancer in the particular country.  Different prognosis tools were 
chosen as alternatives for the comparison according to standard clinical practice in the 
particular country. Meta-analysis results of six published studies on the decision impact 




Table 1.2 CEA studies for 21-gene assay 
Article Country Comparing group Base Case 
Hornberger et 
al. 2005 U.S. NCCN LN-, ER+, HER2-/+, ESBC 





LN-, ER+, HER2-, ESBC 
Kondo et al. 
2008 Japan 
1. NCCN 
2. St Gallen 
55-year old 
LN-, ER+, HER2-/+, ESBC 





LN-, ER+, HER2-, ESBC 
Bacchi et al. 
2010 Brazil 
Web-based 
survey of 30 
Brazilian 
oncologists 
Hypothetical cohort of 100 
patients based on tumor size 
Tsoi et al. 2010 Canada AOL 50-year old women with LN-ER+ HER2- ESBC 





LN-, ER+, HER2-, ESBC 
Hall et al. 2011 UK Adjuvant therapies 
LN+, ER+, HER2-, ESBC 
patients with chemotherapy 
Kondo et al. 
2011 Japan St Gallen 2009 
55-year old 
1.LN-, ER+, ESBC 
2.LN-/+, ER+, ESBC 
Vanderlaan et 
al. 2011 U.S. NCCN 
Disease free case 
(hypothetical cohort of 2 
million with age distribution 
of US population) 
Hornberger et 
al. 2011 U.S. 
Meta-analysis 






1.6.3 Results of Studies 
The majority of studies reported an ICER falling into the range between 2,000 and 
10, 000 USD and concluded that 21-gene assay is considered cost-effective, as shown in 
Table 1.3. For example, Kondo et al. (2011)32 estimated an ICER of US$3,848 
perQALY for the indication for LN- scenario and $5,685 per QALY for the indication 
for LN-/+ scenario, U.S. dollars year 2010 value. Both are not more than the suggested 
social willingness-to-pay for one QALY gained from an innovative medical 
intervention in Japan (US$50,000/QALY). Tsoi et al. (2010)42 reported an ICER of 
$61,800 per QALY, Canadian dollars year 2008 value. And according to the willingness 
to pay thresholds of $50,000 to $100,000 per QALY in Canada, 21-gene assay is still 
considered as cost-effective.  
Other studies, such as Bacchi et al. (2010),43 reported a cost saving of $79,361 for 
100 Brazil breast cancer patients, varying by tumor size, U.S. dollars year 2010 value.  
 
1.7 Gap  
All eleven studies found 21-gene assay cost-effective or cost saving; however, 
none of these studies were done in China. Differences in epidemiology, treatment, and 
healthcare system between the U.S. and China are compared here to illuminate the 
importance of CEA study regarding 21-gene assay in China and why the results from 







Table 1.3 Results of CEA studies for 21-gene assay 
Article Country ICER Conclusion 
Hornberger et 
al. 2005 U.S. N/A 
Cost-effective for RS 
intermediate/high group and 
cost saving for RS low group 
Lyman et al. 
2007 U.S. $4,432 
Cost-effective compared to 
chemotherapy and tamoxifen 
alone 
Kondo et al. 
2008 Japan $26,065/$10,744 
Compare to NCCN and St 
Gallen, 21-gene assay is 
cost-effective 
Cosler et al. 
2009 U.S. $3,385 Cost-effective 
Bacchi et al. 
2010 Brazil N/A 
21-gene assay is cost saving 
in Brazil, vary by tumor size 
Tsoi et al. 2010 Canada $63,064 21-gene assay is cost-effective in Canada 
Klang et al. 
2010 Israel $10,770 
21-gene assay is cost-
effective in Israel. 
Hall et al. 2011 UK $8,852 
21-gene assay –directed 
chemotherapy is cost-
effective 
Kondo et al. 
2011 Japan $3,848/$5,685 
For both LN- and LN-/+, 21-
gene assay is cost-effective 
Vanderlaan et 
al. 2011 U.S. N/A 
For N+(1-3)/ER+ HER2- 
patients, 21-gene assay is 
cost saving 
Hornberger et 
al. 2011 U.S. N/A 
21-gene assay is cost saving 








1.7.1 Epidemiology Differences 
As listed in Table 1.4, approximately 20 women per 100,000 are diagnosed with 
breast cancer each year in China.47 Although the incidence rate is 6 times less than the 
rate in the U.S., the total number of cases is large, both among the highest in the world. 
In 2000, the China National Office for Cancer Prevention and Control reported an  
increasing incidence rate of 37% and an increasing mortality rate of 38.9% over 10 
years in the major cities.48 
In the U.S. there is only a slightly increasing incidence rate trend between 2005 
and 2008 and a consistently decreasing mortality rate from 1990 to 2008.2 These all 
indicate the tremendous public health burden and the huge potential saving by treating 
the patients with breast cancer cost-effectively in China. 
Moreover, characteristics of the disease in the Chinese population also differ from 
the U.S. (Table 1.5). Women with newly diagnosed breast cancer are more likely to be 
premenopausal and are 17 years younger at diagnosis compared to developed 
countries.2,47 There are 19% less ER+ and 6.5% less HER2- patients in China.2,47 Since 
ER+ and HER2- refer to less aggressive breast cancer progression, lower ER+ and 
 





rate* Incidence case Incidence trend 
Mortality 
trend 
U.S. 124.0 23.5 230,480 +0.7 (2005-2008) -2.2(1990-2008) 
China 20 5.5 190,000 +3.7 yearly +3.9 yearly 
Per 100,000 women 
Source: SEER Cancer Statistics2; Li et al. 201147; He et al. 201149; Zhong Guo Ru Xian 
Ai Diao Cha Bao Gao, 201048 
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Table 1.5 Patients’ demographic differences between U.S. and China 
 
Mean age at 
diagnosis Premenopausal ER+ HER2- 
5-year survival 
rate 
U.S. 62 N/A 75% 80% 89.1% 
China 45 62.9% 56% 73.5% Increasing from 50% 
Source: SEER Cancer Statistics2; Li et al. 201147 
 
HER2- proportions indicate China has more severe breast cancer. Although the 5-year 
survival rate of breast cancer in China is increasing from 50% since the 1960s, it is still 
much lower than the 89.1% in the U.S.2,47 According to the WHO health statistics 2009, 
women in the U.S. and China share a similar life expectancy at birth.13 Thus, with 
younger patients, more aggressive disease, and a lower survival rate, the life-year loss 
among breast cancer patients in China is tremendous.  
 
1.7.2 Treatment Differences 
Table 1.6 lists the treatment differences between the U.S. and China. Oncologists 
are following different guidelines in the two countries. In the U.S., multiple guidelines 
are available, such as NCCN, St Gallen, and ASCO. However, the only available breast 
cancer treatment practice guideline used in China is the NCCN Chinese Version, which 
is a translation version of the NCCN in the U.S., updated to 2011, and adjusted by 
Chinese oncologists based on their opinion and practice experience to fit in China.50-52 
For example, for the LN-, ER+, HER2- subset of ESBC patients, U.S. guidelines 
support the new evidence and recommend doxorubicin/cyclophosphamide followed by 
weekly paclitaxel (AC+T) as the standard regimen,16,53 while NCCN Chinese Version  
16	  
 
Table 1.6 Treatment differences between U.S. and China 
 Guideline Chemotherapy 
Chemo 
regimena 21-gene assay 
U.S. Multiple Around 60% AC+T Recommended 
China NCCN Chinese Version 81.4% AC or TC 
Not 
recommended 
aadjuvant therapy for LN-, HR+, HER2- patient  
Source: NCCN breast cancer guideline V1.201216; NCCN breast cancer guideline 
Chinese Version 201150; Li et al. 201147 
 
still recommends doxorubicin/cyclophosphamide (AC) or docetaxel/cyclophosphamide 
(TC).50 
Oncologists in China provide chemotherapy to most breast cancer patients, leading 
to around 20% more patients undergoing chemotherapy, compared with the U.S.16,47 
Meanwhile, 21-gene assay is removed from NCCN Chinese Version for its expensive 
price and lack of prospective study results.50,54  
 
1.7.3 Chinese Health Care System 
Limited resources are also a concern in China. The increasing size of the 
population has been a burden to the whole country and, of course, has influenced the 
quality of health care each person obtains.55,56 Table 1.7 lists numbers of healthcare 
resources between the two countries. It is not hard to see the huge shortage of healthcare 
resource in China relative to the US. For instance, the ratio of nurses and physicians is 
almost equal in China, about 1 each per 1,000 residents.55,57 Yet, others have found a 








on health as 




















China 4.6 216 14 10 22 
United 
States 15.3 6719 26 94 31 
Source: World Health Organization, 200955,57; Ungos et al. 200958 
 
for every physician and 9.4 nurses per 1,000 population. Compared with U.S. patients, 
Chinese patients are spending much less money on healthcare and getting fewer doctors, 
fewer nurses, and limited hospital beds.55-58 This shortage will definitely influence the 
resource utilization when breast cancer patients are treated. 
China also has a unique insurance system, consisting of the New Cooperative 
Medical System for rural residents; employee insurance and resident insurance for 
urban citizens; and supplemental insurance as a government employee benefit, 
catastrophic coverage, and commercial insurance.59 Co-pay for different insurance type 
varies. The rural insurance program only covers 50% of the healthcare expenditure 
while urban insurance coverage usually goes up to 85%. Government employees 
receive full coverage. An entitlement program for elderly residents similar to Medicare 





1.8 Objective of the Study 
With these huge differences in epidemiology, treatment, and healthcare system, we 
cannot easily generalize the results from the U.S. and other developed countries to 
China. Although the cost-effectiveness of 21-gene assay in developed countries is well 
established, the potential economic impact of incorporating the 21-gene assay in China 
is still unknown. To understand the use of the 21-gene assay and whether it leads to 
better health outcomes, economic evaluation from the Chinese health care system’s 
perspective is needed. Hence, this study aims to perform a cost-effectiveness analysis of 
21-gene assay on treatment of ESBC patients in China. 
  




A cost-effectiveness analysis with a decision tree and Markov model was 
performed based on the validation studies of 21-gene assay and published literature. 
Costs were estimated under the Chinese health care system with a sensitivity analysis, 
from the health care provider’s perspective. The model and all analyses were performed 
using TreeAge Pro 2012 Suite (TreeAge, Williamson, MA). 
 
2.1 Base Case  
A hypothetical cohort of 10,000 female patients with LN-, ER+, HER2- early stage 
breast cancer at the age of 45 after either breast-conserving surgery or mastectomy were 
chosen as the base case. Age 45 was chosen according to the average age of women 
with a new breast cancer diagnosed in China.47  Women with LN-, ER+, HER2- early 
stage breast cancer were chosen based on the population recommendations for the 21-
gene assay in major guidelines in United States.16,27,28 
Two scenarios were set up in this model for these patients: continue with NCCN 
Guideline Chinese Edition guided treatment, or receive the 21-gene assay RS guided 
treatment. NCCN Guideline Chinese Edition was chosen as the alternative because it is 
widely adopted in most hospitals in China.52 
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2.2 Decision Tree and Markov Model 
Figure 2.1 shows the decision tree in this model. In the 21-gene assay scenario, 
patients received risk classification by NCCN criteria first, followed by reclassification 
using 21-gene assay RS. In the NCCN scenario, patients only followed the NCCN 
guideline for risk classification. Based on the recommendation in major guidelines, RS 
intermediate-risk patients were grouped together with the RS high-risk patients. An 
assumption was made that 100% of patients who fall in this group would undergo 
adjuvant chemotherapy; similarly, 100% of patients in the high-risk group by NCCN 
criteria would receive chemotherapy. Low-risk patients would not receive 
chemotherapy. Patients receiving chemotherapy may experience no toxicity, grade 1-2 
toxicity, grade 3-4 toxicity, or fatal toxicity. 
The Markov model in Figure 2.2 shows the health states once the adjuvant therapy 
or hormone therapy is completed. Four stages are considered here: (1) disease-free stage 
with no recurrence, which may progress to local recurrence stage, distant/metastatic 
recurrence stage; (2) local recurrence stage, which may transition back to a disease-free 
stage after surgery or progress to distant recurrence; (3) metastatic disease, which is 
currently not curable and therefore can only transition to (4) death.  
The cycle length of each stage was defined as 1 year. Since we calculated the 
probabilities of recurrence transit between stages from 10-year distant recurrence-free 
survival (DRFS10) and the fact that most of the recurrences occur within this time period, 














Figure 2.2. Markov health states 
 
2.3 Probability of Risk Classification 
Data on probabilities of risk classification using NCCN criteria and/or 21-gene 
assay were derived from NSABP B-14 clinical trial (Table 2.1).21 For the 7.9% of 
patients who fall into the low-risk group by NCCN criteria, 28%  were reclassified into 
the intermediate/high group by 21-gene assay; for the 92.1% patients who were 
assigned to the high-risk group by NCCN criteria, 49% were reclassified into the low 











Table 2.1 Probabilities of risk classification 
 Probability (%)  Probability (%)a 
NCCN criteria  21-gene assay  
Low risk 7.9 Low 5.7 
Int/high 2.2 
High risk 92.1 Low 44.9 
Int/high 47.2 
Int/high: intermediate or high 
a Probabilities in this column add up to reflect the probabilities in NCCN group. 
Source: NSABP B-1421 
 
2.4 Probability of Toxicity from Chemotherapy 
Toxicity profiles were adapted from the National Cancer Institute Common 
Toxicity Criteria.61 Based on these criteria, grade 1-2 toxicity refers to mild to moderate 
severity adverse events – no or minimal intervention needed; grade 3-4 toxicity refers to 
severe to life-threatening adverse events – hospitalization needed and limiting self-care 
activities of daily living; and grade 5 refers to fatal toxicity related to adverse events. 
 According to the NCCN Guideline Chinese Edition 2011,50 doxorubicin/ 
cyclophosphamide (AC) and docetaxel/cyclophosphamide (TC) are the two 
recommended standard regimens as adjuvant therapy for lymph-node negative and 
hormone-receptor positive breast cancer patients. Jones et al. (2006)24 stated that TC has 
similar overall toxicities compared to AC, based on the number of patients in each 
toxicity grade. Thus, AC and TC were assumed to have the same toxicity profile and 
AC was chosen as the base case chemotherapy regimen to perform analysis in our 
model. The probabilities of different toxicity measures were obtained from published 
literature from phase 3 randomized clinical trials of AC.23  
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2.5 Risk of Recurrence and Death 
Annual risks of recurrence and survival in different risk classifications were 
derived and calculated from probability of 10-year recurrence rate reported from 
published meta-analysis of clinical trials.62 (Table 2.2) The proportion of local 
recurrence among all recurrence events was 18.75% according to Liubao et al. (2009).51 
A further 30% relative risk reduction of recurrence associated with adjuvant 
chemotherapy plus tamoxifen versus tamoxifen alone were applied for NCCN high-risk 
patients; and for RS intermediate/high-risk patients, 45% relative risk reduction was 
applied.39 
Since the AC regimen was the base case regimen, the risk of recurrence derived 
from the literature reflected the recurrence rate of the AC regimen; and the probabilities 
of recurrence for the TC regimen were estimated by multiplying the probabilities for 
AC by hazard ratio derived from the results of ACTC trial.24,53 
Once patients developed recurrence, it was assumed that the transition probabilities 
were identical in all patients, regardless of their risk group and treatment. The 
probabilities of local recurrence to distant recurrence were adapted from the meta-
analysis results from Liubao et al. (2009).51 The average life-span for patients 
developing distant recurrence is 21 months. For non-breast cancer related death, the 
probabilities were derived from 2009 life tables for Chinese women from the WHO. 
 
2.6 Utilities 
A utility weight was assigned to each health state as an estimate of the quality-
adjusted life-year (QALY) gains. Perfect health is expressed as a utility weight of 1;  
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Table 2.2  Transition probabilities 
 Base case value Range tested in 
sensitivity analysis 
Probability of distant recurrence by 10 
years62 
  
NCCN low 7.8% Change by ±50% 
NCCN high 21.9% Change by ±50% 
Relative risk reduction with 
chemotherapy 
  
NCCN high39,42 30% 95% CI 
RS int/high39,62 45% 95% CI 
Probability of chemotherapy toxicity23   
Grade 1-2 68.5% Change by ±50% 
Grade 3-4 27.3% Change by ±50% 
Fatal 0.1% Change by ±50% 
Hazard ratio for TC, compared to 
AC24,53 
0.74 95% CI 
Probability of death   
Average length of life in patients 
developed distant recurrence59,63 
21 months Change by ±50% 
Non-breast cancer death over 10 
years55 
Based on statistical life 
table of Chinese women, 
2009 
Change by ±50% 
Probability of local recurrence if 
recurrence occurs24,51 
18.75% Change by ±50% 
Probability of local recurrence to 
distant recurrence51,64-66 
Based on published 
literature 
Change by ±50% 
 
poorer quality of life leads to lower utility while death is represented as 0 weight. 
Utilities were derived from published literature67-70 and the Tufts/Harvard cost-
effectiveness analysis registry71 (Table 2.3). 
As shown in Table 2.3, the utility weights associated with chemotherapy without 
toxicity, chemotherapy with grade 1-2 toxicity, and chemotherapy with grade 3-4 
toxicity were assumed as 0.74, 0.70, and 0.60, respectively. For the no recurrence state, 
the local recurrence state, and the distant recurrence state, the utilities each year as they 
stayed in the state were 0.90, 0.70, and 0.50, respectively. 
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Table 2.3 Utilities weight 
 Base case value Range tested in sensitivity 
analysis 
Toxicity   
    No toxicity68-71 0.74 Change by ±20% 
    Grade 1-267 0.70 Change by ±20% 
    Grade 3-467 0.60 Change by ±20% 
No recurrence68,70,71 0.90 Change by ±20% 
Local recurrence68,70,71 0.70 Change by ±20% 
Distant recurrence68,70,71 0.50 Change by ±20% 




This study was from a Chinese health care provider perspective, thus, only direct 
medical costs were considered. Direct nonmedical costs such as transportation and 
indirect costs such as loss of productivity were excluded. All costs were expressed in 
Chinese Yuan (CNY), 2008 value and translated to U.S. Dollar (USD) at the rate of $1 
= 6.834 CNY, as of January 2009. A 3% discount rate per year was applied to all costs. 
 
2.7.2 Cost Estimation of 21-gene Assay 
Since manufacturer’s suggested retail price for 21-gene assay in China is not 
available, its price was estimated according to the differences between chemotherapy 
drug costs in China and the U.S.  
As to the sensitivity analysis range of the cost of 21-gene assay, since 50% upper 
and lower bounds does not span the retail price ($3 975, effective July 1, 2009) in the 
U.S.,39 a wider range, CNY4 043 to CNY 27 165 ($591 to $3 975), was utilized to cover 
the lower 50% bound of the estimated price in China and its retail price in the U.S. 
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2.7.3 Costs input  
The major cost inputs in this study were derived from Liubao et al. (2009),51 
including costs associated with chemotherapy, chemotherapy toxicity, recurrence 
treatment, and follow-up and end-of-life health care (Table 2.4). This was a cost-
effectiveness study comparing the TC and AC regimen in early stage breast cancer 
patients from a Chinese health care provider perspective. All costs data and resource 
utilization information were collected from the Second Xiangya Hospital of Central 
South University in Changsha, China. This is one of the most famous and first-class  
hospitals in China. In Hunan Province, about one-third of breast cancer patients were 
treated in this hospital. In addition, oncologists in this hospital follow the Chinese 
edition of the NCCN Guidelines.51 Thus, costs from this study were chosen as the base 
case. In China, an economic gap exists among the different geographical areas, so we 
addressed this issue in the sensitivity analysis. 
The costs of chemotherapy included cost of the chemotherapy agents, 
administration, and supportive treatments. Three days of hospitalization for each cycle 
and body surface area of 1.6 m2 representing the average Chinese woman’s body size 
were used. The drug acquisition for regimens were: AC, Doxorubicin 60 mg/m2, 
Cyclophosphamide 600 mg/m2, every 21 days for 4 cycles; TC, Docetaxel 75 mg/m2,  
Cyclophosphamide 600 mg/m2, cycled every 21 days for 4 cycles. Again, cost of the 
AC regimen was the base case. The cost of grade 1-2 toxicity was included in the costs 
of chemotherapy treatment. The cost of grade 3-4 toxicity incorporated hospitalization, 
management, and medication costs of grade 3-4 toxicity events (nausea and vomiting, 
febrile neutropenia and neutropenia) per cycle. Based on the NCCN Guideline, the cost 
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Table 2.4 Costs (Chinese Yuan, year 2008 values)  
 Base case 
value 
Range tested in 
sensitivity analysis 
21-gene assay (Oncotype DX) 8 086 4 043 ~ 27 165 
Tamoxifen/per year51 638 Change by 50% 
Chemotherapy/per cycle   
    AC51 2 021 Change by 50% 
    TC51 5 742 Change by 50% 
Treatment for toxicity/per cycle   
    Grade 3-451 2 427 Change by  50% 
Treatment for local recurrence/per year51 82 730 Change by  50% 
Treatment for distant recurrence/per year51 93 660 Change by  50% 
Follow-up for disease-free/per year51 1 846 Change by  50% 
Follow-up for local recurrence/per year51 1 846 Change by  50% 
Follow-up for distance recurrence/per year51 78 050 Change by  50% 
Terminal 3 month51 39 179 Change by  50% 
Discount rate 3% 0 to 5% 
 
of tamoxifen was applied to all patients for 5 years or until the development of distant 
recurrence or death. The costs of treatment for recurrence, follow-up, and terminal care 




The model estimated the total direct health care costs and QALY for 21-gene assay 
guided treatment and NCCN guideline guided treatment, and also the incremental cost 
per QALY gained – incremental cost-effectiveness ratio (ICER). ICER was calculated 





2.9 Sensitivity Analysis 
In order to assess the robustness of the results obtained from the model, one-way 
sensitivity analysis was performed on all variables. The ranges used in the one-way 
sensitivity analysis were derived from a review of the existing literature. In the case of a 
lack of data, a range of 50% lower and upper bound was considered for the cost 
variables and 95% confidence interval as the range was considered for the clinical 
variables.    
In particular, the starting age of the cohort was varied from 35 to 55 years old; 
relative risk reductions and hazard ratio for TC adopted the 95% confidence interval 
range, while the rest of the probabilities were changed by ±  50%; following Kondo et al. 
2008, utility weights were all varied by  20%; costs were all varied by  50%, 
except for the cost of 21-gene assay; the discount rate was changed from 0 to 5%. 
Tornado diagrams were used to assess the importance and possible influence of the 
choice ranges for sensitivity analysis.  
  




Results of the decision tree and Markov model are displayed in the following 
section. Base case cost-effectiveness analysis was performed first, followed by one-way 
sensitivity analysis to test the robustness of the model. A tornado diagram is presented 
to demonstrate the result of the sensitivity analysis and stability of the ICER. At the end, 
the model was rerun by replacing the cost and recurrence rate of base case 
chemotherapy with AC by TC regimen. 
 
3.1 Cost-effectiveness 
Table 3.1 shows the results of the base case cost-effectiveness analysis of 21-gene 
assay-guided treatment, among LN-, ER+, HER2-, early stage breast cancer Chinese 
patients. The total cost of the 21-gene assay-guided treatment in a 45-year-old patient 
was estimated as ?87 786 (US$12 845), compared with the NCCN-guided treatment of 
?98 912 (US$14 473), which results in a cost saving of ?11 125 (US$1 628). The 21-
gene assay-guided treatment was associated with a QALY of 8.63 year, compared with 
a QALY of 8.33 year for the NCCN-guided treatment, with an incremental QALY of 
0.30 year. The ICER of the NCCN-guided treatment versus 21-gene assay treatment is 
dominated, with a value of  -37 141 ?/QALY (5 435 US$/QALY), which means 21- 
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87 786 -11 125 8.63 0.30 Dominant 
NCCN-guided 98 912  8.33   
Abbreviation: QALY, quality-adjusted life year; ICER, incremental cost-effectiveness 
ratio 
 
gene assay-guided treatment is less expensive and more effective than NCCN-guided 
treatment. 
 
3.2 Sensitivity Analyses 
The results of the one-way sensitivity analysis are shown in Figure 3.1. Twelve 
variables are listed by the order of magnitudes of the ICER range. The model results 
were not sensitive to variables not listed in the figure. 
Twenty-one gene assay-guided treatment is cost saving and more effective for 
most of the variables, with three exceptions: (1) cost of 21-gene assay; (2) probability of 
being assigned to a high-risk group based on NCCN guideline criteria; (3) probability of 
10-year recurrence rate for NCCN high-risk group patients. If the cost of 21-gene assay 
in China equals the retail suggested price in the U.S. (?27 165, US$3 975), then the 
21-gene assay-guided treatment will be cost increasing; the cost per QALY gained 
would be ?26 551 (US$ 3 885). If only 46.1% of patients (50% of the base case) were 
classified into the high-risk group, the 21-gene assay-guided treatment would still be 
more effective but with higher total cost, with an ICER of 21 572 ?/QALY (3 156 
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Figure 3.1 Results of sensitivity analyses 
 
US$/QALY). Probability of 10-year distant recurrence calculated based on DRFS10 also 
had a large impact on the results. If NCCN high-risk patients had a lower probability of 
10-year distant recurrence, 11% vs. 50% in the base case, the 21-gene assay-guided 
treatment would be QALY gained and cost increasing, with an ICER of 9 218 
?/QALY (1 349 US$/QALY). 
 Twenty-one gene assay is dominant for other variables, including other cost inputs, 
other probability inputs, utility weights, discount rate, and patient age at diagnosis. 
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3.3 Results for TC Regimen 
After rerunning the model by changing the chemotherapy regimen to TC, similar 
results were obtained  (Table 3.2, Figure 3.2). Compared to the base case using the AC 
chemotherapy regimen, TC regimen resulted in a larger cost-saving Y13 285 (US$ 1 
934) and less benefit gain of 0.24 QALY for the 21-gene assay-guided treatment. 
NCCN-guided treatment is still dominated by 21-gene assay treatment with a negative 
ICER (-54 566?/QALY, 7 984 US$/QALY).  
In sensitivity analysis with TC regimen, only the cost of 21-gene assay and 
probability of being in the high-risk group based on NCCN guideline criteria would 
change the sign of the ICER. Similarly to analysis with the AC regimen, having the U.S. 
retail price as the cost of 21-gene assay would result in a higher expenditure for 21-gene 
assay-guided treatment and the cost per QALY would be ?23 795 (US$3 482). 
Compared with analysis with AC regimen, the probability of being high-risk by NCCN 
criteria became a more sensitive variable with a larger range in the TC model; the cost 
per QALY would be ?33 429 (US$4 891) if probability were changed to 46.05%. 
In both analysis with the AC regimen and the TC regimen, results are consistent 
























86 692 -13 285 8.74 0.24 Dominant 
NCCN-guided 99 978  8.50   





Figure 3.2 Results of sensitivity analysis with TC regimen 
  




The cost-effectiveness of 21-gene assay in the Chinese health care system was 
evaluated in this study for LN-, ER+, HER2-, ESBC patients. The results indicate, 
regardless of the chemotherapy regimen, compared to traditional guideline-based 
treatment, the diffusion of 21-gene assay gains more QALYs and saves money at the 
same time. Unless otherwise specified, the analysis in this chapter is based on base case 
analysis with AC regimen. 
AC and TC are the two adjuvant chemotherapy regimens NCCN Guideline 
Chinese Version recommended for this patient cohort.50 Under the base case analysis 
with AC regimen, 21-gene assay saves ?11 125 (US$1 628) with a higher QALY of 
0.30 year per patient over 10 years. Replacing the chemotherapy with TC regimen 
results in an even larger cost saving of ?13 285 (US$ 1 934) but less effective gain of 
0.24 year for treatment guided by 21-gene assay. This is due to the higher cost and 
lower recurrence rate of TC.51 Studies have shown that in both the short term and long 
term, TC is associated with superior clinical outcomes to standard AC, regardless of 
patient age.24,53 NCCN guideline 2012 version has removed AC from the recommended 
chemotherapy for HR+ patients.16 Meanwhile, Liubao et al. indicated that compared 
with AC, TC is considered cost-effective in China with an acceptable ICER of ?24 305 
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(US$3 556) per QALY.51  It is expected that future updates to the Chinese Version of 
the NCCN Guidelines, will also replace AC with TC or another superior regimen. 
However, in our model the results are not sensitive to the cost and toxicity profile of the 
chemotherapy regimen. With either AC or TC as the adjuvant chemotherapy, NCCN-
guided treatment is strictly dominated by the 21-gene assay-guided treatment.  
The cost of 21-gene assay appears to be the major determinant of cost-
effectiveness in our sensitivity analysis. Due to the unavailability of a retail price in 
China, the cost of the assay in the base case analysis is estimated as almost three times 
less than the U.S. price, based on the price differences among chemotherapy drugs 
between the two countries. Another price estimation strategy is setting the price 
compared to per capita GDP; according to the International Monetary Fund 2011, per 
capita GDP in China (US$8 382) is 5.7 times less than per capita GDP in the United 
States (US$48 387), which results in an even lower price for 21-gene assay.72 A lower 
price of the 21-gene assay would contribute to an even larger cost savings for treatment 
guided by 21-gene assay. Even if the price is identical to the U.S. retail price as ?27 
165 ($3 975)37, and the application of the assay become cost increasing, the ICER per 
QALY calculated as ?26 551 (US$ 3 885) is still considered as cost-effective in terms 
of U.S. willingness-to-pay (US$50 000 or US$100 000 per QALY). Currently, China 
has no official guideline on the willingness-to-pay threshold. If China adopts the 
WHO’s definition73: (1) highly cost-effective if ICER is less than GDP per capita; (2) 
cost-effective if ICER is between 1 and 3 times of GDP per capita; (3) not cost-effective 
if ICER is higher than 3 times GDP per capita, 21-gene assay-guided treatment would 
be considered as highly cost-effective with a price as high as the U.S. retail price. 
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Probability of risk classification by NCCN guideline becomes the second major 
factor in sensitivity analysis. The more accurate the NCCN risk classification becomes, 
the less cost-effective 21-gene assay becomes. In our sensitivity analysis, even if the 
NCCN guideline only recommends 46.05% patients to additional chemotherapy, the 
ICER of 21 572 ?/QALY (3 156 US$/QALY) is still considered as highly cost-
effective for 21-gene assay-guided treatment in terms of WHO thresholds. This 
situation is not likely to occur. Studies have shown NCCN guidelines tend to 
overestimate the recurrence risk and recommends adjuvant chemotherapy for most 
patients.25 After all, 21-gene assay was specifically developed to solve the inaccurate 
risk classification problem of traditional guidelines.  
Cost-effectiveness of 21-gene assay has been reported by 11 studies ever since the 
first validation clinical trial regarding this topic done in 2004.32,37-46 They all 
demonstrated its superiority over traditional prognostic pathways of risk classification. 
Most studies demonstrated 21-gene assay would increase the cost and improve the 
quality of life with an acceptable ICER for 21-gene assay.32,38-40,42,44-46 For example, 
Kondo et al. found an ICER of US$26 065 per QALY based on U.S. validation study in 
2008 and an ICER of US$3 848 per QALY based on Japanese validation study in 2011, 
in the comparison between NCCN-guided treatment and assay-guided treatment.  
A few studies considered treatment guided by 21-gene assay as a less expensive 
strategy.37,39,41,43 Hornberger et al. found an acceptable ICER of US$31 452 per QALY 
for RS intermediate/high-risk patient and a cost saving for RS low-risk patient in 2005 
and reported an average cost saving for US$1 160 per patient associated with 21-gene 
assay-guided treatment based on real-world cost reimbursement data in 2011. A study 
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conducted in Brazil, a developing country, found a cost saving of US$794 per patient on 
direct medical cost when applying 21-gene assay in 2010. Results of our study indicate 
a cost saving of US$1 628 per patient with AC regimen and US$1 934 per patient with 
TC regimen, which is consistent with the results of these studies.  
Our study did not result in an increasing cost for 21-gene assay. This may be due 
to several reasons. First, a different perspective was utilized. Societal perspective is 
applied for most studies while health care provider perspective was adopted in this 
study which only accounts for the direct medical costs. Second, a lower price of 21-
gene assay was used. According to our sensitivity analysis, cost of 21-gene assay is the 
major sensitive variable, and all of the 11 studies adopted a similar price to the U.S. 
retail price (around US$4 000), while our study made a cost estimation based on the 
cost difference on chemotherapy drugs and applied a much lower price (US$1 183), 
which may contribute to the different results. Third, different alternatives were used. 
For instance, in the study by Tosi et al., AOL, the alternative prognosis tool, only 
recommends 47% of the patients for chemotherapy. As we know from our sensitivity 
analysis, probability of risk classification by the alternative strategy is very sensitive to 
the results. Thus, a different alternative with a different power of risk classification in 
the comparison with 21-gene assay would influence the results.  
 
4.1 Significance of This Work 
As the most prevalent cancer among women, breast cancer is a significant burden 
of illness all over the world. The total cost of new breast cancer cases in Asia in 2009 is 
around US$1 928 million.4 With increasing incidence rate and mortality rate,47 the 
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economic burden of breast cancer in China will inevitably become an important 
question.  Meanwhile, Chinese breast cancer patients are 17 years younger than in 
developing countries, with more aggressive disease and lower survival rates, which 
results in an enormous life-year loss.55-58  Given the limited health care resources in 
China and the growing cost of the health care system, the economic evaluation of new 
health technology is warranted.  
Our results indicate 21-gene assay contributes to a cost saving of ?11 125 (US$1 
628) per patient in China. For 190,000 breast cancer incidence cases in 2009,47,49 this 
assay could save ?105 million (US$15.5 million) for the country, if half of the patients 
would receive the assay. Meanwhile, better effectiveness is associated with the diffusion 
of 21-gene assay. We believe our model will help the decision makers in China make 
informed decisions to achieve better health outcomes and avoid unnecessary cost.  
In China, the development of pharmacoeconomics is tardy, and the 
acknowledgement of the need for pharmacoeconomics is still inadequate.74 However, in 
2009, the Chinese government announced an official reform policy to providing 
universal access to healthcare services and formulating a national essential medicine 
system with government price guidelines.75 In this reform, pharmacoeconomic 
evaluation was stated as the crucial criteria to form the essential medication list.76 With 
the publication of draft Chinese pharmacoeconomics guidelines in 2006 and more and 
more cost-effectiveness studies in recent years, the awareness of the importance of 





This study has some potential limitations. First, our model depends on the 21-gene 
assay validation studies performed in the U.S. Although evidence applied in the model 
are from the best available knowledge, the differences of characteristics between 
Chinese patients and U.S. patients might still lead to differences in clinical outcomes. 
We tested these differences by sensitivity analysis, varying the probabilities ±50% and 
the clinical outcomes (e.g., relative risk reduction, hazard ratio for TC compared with 
AC) in the 95% confidence interval range. And the results are robust to these changes.  
Second, cost values in this study were from one local hospital. Generally, 
medication costs account for the majority of the total treatment costs, and within the 
same Chinese geographical area, the costs of most drugs should remain the same. 
Across regions, economic gaps do exist, especially between rural and urban areas. 
According to the statistics of the National Bureau, in 2009, the urban-rural income ratio 
was 3.33 to 1.77 And these economic gaps will inevitably influence the drug prices. Our 
cost data source, the Second Xiangya Hospital of Central South University, is an upper-
first-class hospital in Hunan province, a province with a midrange GDP per capita 
across the country, which makes this data source a rational base case for the sensitivity 
analysis to address the cost variation problem. 
Third, utility weights adopted in this study were derived from Western reports. 
Usually, utility weights are different across countries, especially in Asian populations 
compared to Western populations. However, utility estimations for breast cancer 
patients are not available in China, nor in other Asian countries, and we can only 
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address this problem by generalizing the Western utilities on Chinese patients and vary 
the values by sensitivity analysis.  
Fourth, toxicity profiles regarding the toxicity grade groups were derived from a 
clinical trial 22 years ago.23 With the advance in care management and adverse event 
treatment, the clinical outcomes for toxicity have improved from that time. However, in 
the later studies, probabilities for a unique patient to experience toxicity during 
chemotherapy treatment are not available. Mamounas et al. found 0.3% of fatal toxicity 
for AC regimen in the study in 2005, comparing with paclitaxel plus AC.78 Jones et al. 
stated no fatal toxicity during AC regimen and 0.3% of fatal toxicity during TC regimen. 
They also found around 10% of the patients would develop grade 3-4 neutropenia in 
either AC regimen or TC regimen.24 With the risk of other grade 3-4 adverse events, 
such as infection, fever, and asthenia, we can expect higher probability of developing 
grade 3-4 toxicity for individual patients. These results are similar to the toxicity profile 
in our model .  
 
4.3 Future Work 
Future work includes expanding this study to lymph-node positive patients in 
China, since the prognostic value of 21-gene assay for these patients has been studied 
and reported by TransATAC and SWOG-8848 recently. Once benefit of chemotherapy 
for the intermediate-risk group being identified by the ongoing RxPONDER and 
TAILORx trial, further economic evaluation reflecting this change will become 
imperative.  
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To better understand the usefulness of 21-gene assay on Chinese patients, a 
Chinese validation study is needed for health managers to decide whether it fits in the 
clinical practice and health care system in China. In addition, further research should be 
undertaken to develop Chinese-specific quality of life instruments for use in the 
emerging pharmacoeconomics, in both urban and rural areas. Economic studies from a 
societal perspective with the life-year loss as the clinical outcome are needed. Also, 




Twenty-one gene assay-guided treatment for lymph-node negative, ER positive, 
HER2 negative early stage breast cancer patients is considered cost saving and more 
effective compared with NCCN guideline-guided treatment from a Chinese health care 
system perspective. The results of this study should assist in making better clinical 
decisions for oncologists and patients as well as be interesting to health managers in 
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